Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Continuing our series highlighting recent presentations from Nursing in Practice 365 events, diabetes specialist midwife ...

High-intensity interval training was associated with improved glycemic control and cardiometabolic outcomes among patients with type 2 diabetes.

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...

Alkem Laboratories on Wednesday said it has launched a generic medication for the treatment of type-2 diabetes mellitus, ...

The Ukrainian Diabetic Federation (UDF) is launching a YouTube channel and Diabetic School for journalists and bloggers to ...

Alkem Laboratories has launched a generic medication for type-2 diabetes, chronic kidney disease and heart failure in India ...

Chief Minister Punjab Maryam Nawaz Sharif in her message on World Kidney Day, while paying tribute to all people who donate ...

Dr Phelisa Sogayise, a nephrologist at Christiaan Barnard and Blaauberg Nectare Hospital in Cape Town, said people with any ...

Observing that the country has become the fifth-largest economy in the world and aims to become number one, Singh said more ...

This came after Hetero Labs presented the BE study protocol, vide no. AZBE112405, Version No. 01, Dated 15.11.2024 and the ...

Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic ...